Use of combretastatin A4 and its prodrugs as an immune enhancing therapy
AssigneesOXiGENE, Inc., Bristol-Myers Squibb Company
InventorsRonald W. Pero, Francis Y.F. Lee, Klaus Edvardsen, Hans Olov Sjogren
Life of this patent
Estimating the term…
Abstract
A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.
Claims14
A method of treating immunosuppression in a warm-blooded animal, comprising administering to the animal an amount of a composition selected from the group consisting of combretastatin A4, prodrugs thereof, and mixtures thereof, effective to enhance immune responsiveness without causing vascular destruction.
A method of treating a warm-blooded animal bearing a tumor, comprising
- (a) subjecting the animal to immunotherapy to inhibit or kill tumor cells, while
- (b) administering to the animal an amount of a composition selected from the group consisting of combretastatin A4, prodrugs thereof, and mixtures thereof, effective to enhance immune responsiveness.
A method of treating a warm-blooded animal bearing a tumor and exhibiting tumor-induced immunosuppression, comprising subjecting the animal to immune-response-enhancing therapy while administering to the animal an amount of a composition selected from the group consisting of combretastatin A4, prodrugs thereof, and mixtures thereof, effective to reduce immunosuppression but insufficient to effect substantial destruction of tumor vasculature.
Dependencies are inferred from the claim text.